A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

drug protocol number
D5160C00007
drug sponsor
AstraZeneca
drug study
Osimertinib (AZD9291)
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Terminated
drug phase